Pfizer says cancer drug succeeds in trial

NEW YORK — Pfizer Inc. said Thursday it ended a successful trial of its cancer drug Sutent early after data showed the drug met its goal of slowing the progression of pancreatic cancer.

NEW YORK — Pfizer Inc. said Thursday it ended a successful trial of its cancer drug Sutent early after data showed the drug met its goal of slowing the progression of pancreatic cancer.

The trial showed that Sutent significantly improved progression-free survival, meaning it extended the time patients survived and their disease did not spread, compared to a combination of standard treatment and a placebo. Because the trial was halted early, patients will have the option to keep taking Sutent or switch to Sutent from the standard treatment.

Pfizer hopes to have the drug approved as a treatment for advanced tumors in the islet cells of the pancreas, and the ending of the trial speeds up Pfizer’s path to approval. Sutent is already marketed for renal cell carcinoma and as a secondary treatment for gastrointestinal stromal tumors.

Pfizer stopped the trial after getting a positive recommendation from an independent committee. The company described the cancer as rare, with limited options for treatment.

______

To read the rest of this article, subscribe to our digital or paper edition.  For previous editions, contact us for details.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Comments

From the Web